Identifying the functional impact of ZNF688 autoantibodies in oral lupus lesions
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Abstract Discoid lupus is a form of cutaneous lupus erythematosus (CCLE) that primarily affects the skin, as well as the oral and nasal mucosa. It is a rare condition, with an estimated prevalence of 3-7 cases per 100,000 people in the United States. Lupus erythematosus, including its cutaneous variants, is characterized by the presence of autoantibodies targeting various self-antigens. While autoantibodies that bind to oral epithelial cells have been identified in lupus, their relevance to mucosal discoid lesions and the specific autoantigens involved remain unclear. This proposal responds to the NIH funding announcement PAR25-122, which supports pilot projects investigating understudied proteins associated with rare diseases like discoid lupus. Among the genes high- lighted in this announcement is ZNF688, a transcription factor belonging to the Krüppel-associated box (KRAB)- zinc finger proteins (KZNFs). KZNFs are primarily known to act as transcriptional repressors, regulating critical cellular processes such as proliferation, differentiation, apoptosis, and genome stability. ZNF688 is particularly intriguing for this funding opportunity due to its underexplored nature, with only four publications on the topic available in PubMed. Notably, two of these studies suggest that ZNF688 is a target of autoantibodies in both lupus and another immune-mediated disease, sarcoidosis. Preliminary data have shown high expression levels of ZNF688 in oral epithelial cells, leading to the central hypothesis of this proposal: ZNF688 may regulate oral epithelial cell function, and autoantibodies targeting ZNF688 could contribute to the pathogenesis of oral lesions in discoid lupus. The proposed studies will investigate whether antibodies against ZNF688 affect the differentia- tion or survival of oral epithelial cells. Additionally, the research will identify target genes and pathways regulated by ZNF688, providing insight into how autoantibodies binding this protein may disrupt oral epithelial cell func- tions. The significance of these studies lies in their potential to: (1) Determine whether antibodies targeting ZNF688 influence cell survival or proliferation. (2) Uncover the target genes and pathways regulated by this understudied transcription factor. (3) Shed light on the potential roles of ZNF688 in the pathophysiology of discoid lupus, a rare disease.
Grant Summary
Identifying the functional impact of ZNF688 autoantibodies in oral lupus lesions is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $160K for university, nonprofit, healthcare org. Applications are due 2027-03-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $160K
2027-03-31
- 1Confirm your organization is eligible for Identifying the functional impact of ZNF688 autoantibodies in oral lupus lesions from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Identifying the functional impact of ZNF688 autoantibodies in oral lupus lesions: Frequently Asked Questions
Who is eligible for the Identifying the functional impact of ZNF688 autoantibodies in oral lupus lesions?
Identifying the functional impact of ZNF688 autoantibodies in oral lupus lesions is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Identifying the functional impact of ZNF688 autoantibodies in oral lupus lesions provide?
Identifying the functional impact of ZNF688 autoantibodies in oral lupus lesions provides up to $160K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Identifying the functional impact of ZNF688 autoantibodies in oral lupus lesions deadline?
Applications for Identifying the functional impact of ZNF688 autoantibodies in oral lupus lesions are due 2027-03-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Identifying the functional impact of ZNF688 autoantibodies in oral lupus lesions?
To apply for Identifying the functional impact of ZNF688 autoantibodies in oral lupus lesions, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.